First reported by ft.com
AstraZeneca shares slide 9% after heart treatment disappoints in trial
AstraZeneca’s Wainua fails main goal in late-stage heart disease trial
6h agoen
From the article
Drug developed with Ionis could not reduce cardiovascular deaths or recurring heart problems
Continue reading on thehindubusinessline.comYou might also wanna read
AstraZeneca shares slide 9% after heart treatment disappoints in trial
ft.com·6h ago
Astrazeneca shares fall 9% after Wainua heart drug fails Phase 3 trial
Astrazeneca's stock dropped 9.1% after disappointing Phase 3 trial results for its heart drug Wainua. Over 140 weeks, the drug failed to sta
finans.dk·5h agoDividenden-Garant Astrazeneca im freien Fall: Studien-Flop schockt Anleger
aktiencheck.de
Astrazeneca-Kandidat Wainua verfehlt Ziel in klinischer Studie - Aktie sackt ab
aktiencheck.de
AstraZeneca enttäuscht mit Wainua: Phase-3-Ziel verfehlt, Aktie deutlich schwächer
IT BOLTWISE·5h ago
AstraZeneca to pull breast cancer and endometriosis drug Zoladex from Australian market in November
AstraZeneca is removing the breast cancer and endometriosis drug Zoladex from Australia's Pharmaceutical Benefits Scheme (PBS) and private m
theguardian.com·28d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.